Evidence map›Paper›PMID 17647026›Full record

ArticlePediatric nephrology (Berlin, Germany)2007

Mechanisms of progression of chronic kidney disease.

Agnes B Fogo

Open access · hybridAbstract read
In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
110citing papers in PubMed, 3 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

110 citing papers in PubMed, 3 syntheses or guidelines pooled it, 260 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Observational
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

50 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Agnes B FogoDepartment of Pathology, Vanderbilt University Medical Center, MCN C3310, Nashville, TN 37232, USA. agnes.fogo@vanderbilt.edu
Vanderbilt University Medical Center · US

Funding

ROLE OF SCAVENGER RECEPTORS IN RENAL FIBROSISP50DK044757 · NIDDK · VANDERBILT UNIVERSITY · PI FOGO, AGNES B. · 1992 to 2011
$11.5M
RESOLUTION OF GLOMERULOSCLEROSISR01DK056942 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI FOGO, AGNES B. · 2001 to 2021
$4.9M
NIDDK NIH HHS DK 44757NIDDK NIH HHS DK 56942NIDDK NIH HHS P50 DK044757NIDDK NIH HHS R01 DK056942
6 · The paper itself

Abstract

Chronic kidney disease (CKD) occurs in all age groups, including children. Regardless of the underlying cause, CKD is characterized by progressive scarring that ultimately affects all structures of the kidney. The relentless progression of CKD is postulated to result from a self-perpetuating vicious cycle of fibrosis activated after initial injury. We will review possible mechanisms of progressive renal damage, including systemic and glomerular hypertension, various cytokines and growth factors, with special emphasis on the renin-angiotensin-aldosterone system (RAAS), podocyte loss, dyslipidemia and proteinuria. We will also discuss possible specific mechanisms of tubulointerstitial fibrosis that are not dependent on glomerulosclerosis, and possible underlying predispositions for CKD, such as genetic factors and low nephron number.

Indexed as

AdolescentChildChronic DiseaseDisease ProgressionDyslipidemiasFemaleFibrosisGenetic Predisposition to DiseaseHumansHypertension, RenalKidney DiseasesMalePodocytesPolymorphism, GeneticProteinuriaRenin-Angiotensin SystemTransforming Growth Factor beta

Identifiers

PMID17647026
PMCPMC2064942
OpenAlexW2162024627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.